Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath-1H induction plus tacrolimus in primary heart transplantation
2006-005275-18Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2007
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of alemtuzumab and tacrolimus in Cardiac Rejection, sponsored by Astellas Pharma. Primary endpoints: Incidence and severity of acute and chronic rejection or time to first acute rejection and Patient and graft survival at month 3. Started Dec 2007; status: completed.
02
Drugs
alemtuzumabtacrolimus
03
Conditions
Cardiac Rejection
Beyond the preview
Go deeper on 2006-005275-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005275-18.